Öztürk Ömür, Sezen Gülbin Yalçın, Ankaralı Handan, Özlü Onur, Demiraran Yavuz, Ateş Hakan, Dost Burhan
Department of Anaesthesiology and Reanimation, Kafkas University School of Medicine, Kars, Turkey.
Department of Anaesthesiology and Reanimation, Düzce University School of Medicine, Düzce, Turkey.
Turk J Anaesthesiol Reanim. 2016 Aug;44(4):206-211. doi: 10.5152/TJAR.2016.97720. Epub 2016 Aug 1.
Rocuronium is a non-depolarising, intermediate-acting, monoquaternary amino steroid and was brought into clinical use as a potentially ideal muscle relaxant. Post-operative residual curarisation (PORC) results from the prolonged effects of non-depolarising neuromuscular blocking agents. This is a common problem and seriously affects patient safety. No recent study has investigated the effects of sugammadex on smokers, which is often used to restore neuromuscular block and avoid PORC. This study compares the severity of the effects of sugammadex used for antagonising rocuronium bromide and antagonism durations in smokers and non-smokers.
This randomised, prospective study included 40 patients scheduled for elective surgery and belonging to classes I and II based the American Society of Anesthesiologists classification, who were either smokers for at least 10 years or non-smokers. Patients underwent routine and neuromuscular monitoring. At induction, 2 mg kg propofol and 1 mcg kg intravenous fentanyl were applied. After the loss of eyelash reflex, 0.6 mg kg intravenous rocuronium was administered. Patients were intubated at train of four (TOF) 2. Anaesthesia was continued with 50% O+50% air and 2% sevoflurane. Rocuronium, 0.15 mg kg, was administered at TOF 2 during the operation. At the end of the operation, 2 mg kg sugammadex was administered. The times until TOF 0.7, 0.8 and 0.9 were recorded.
Intubation time was 132.8±46.4 s for smokers and 127.6±32.7 s for non-smokers. After sugammadex administration, the time to TOF 0.7 was 153.3±54.7 s in smokers and 125±67.2 s in non-smokers. The times were 178.4±58.8 and 146.6±72.6 s for TOF 0.8 and 200.8±55.8 s and 170.4±77.8 s for TOF 0.9 in smokers and non-smokers, respectively.
Although not statistically significant, the time to reach each TOF was longer for smokers. Larger populations and different perspectives are needed to find if sugammadex use is affected by smoking, which has negative effects on the body.
罗库溴铵是一种非去极化、中效、单季铵氨基甾体类药物,作为一种潜在的理想肌肉松弛剂被引入临床使用。术后残余肌松(PORC)是由非去极化神经肌肉阻滞剂的延长作用导致的。这是一个常见问题,严重影响患者安全。近期没有研究调查过舒更葡糖钠对吸烟者的影响,舒更葡糖钠常用于恢复神经肌肉阻滞并避免PORC。本研究比较了舒更葡糖钠用于拮抗溴化罗库溴铵时在吸烟者和非吸烟者中的效应严重程度及拮抗持续时间。
这项随机、前瞻性研究纳入了40例计划接受择期手术的患者,根据美国麻醉医师协会分级为Ⅰ级和Ⅱ级,他们要么是至少吸烟10年的吸烟者,要么是非吸烟者。患者接受常规和神经肌肉监测。诱导时,静脉注射2mg/kg丙泊酚和1μg/kg芬太尼。睫毛反射消失后,静脉注射0.6mg/kg罗库溴铵。四个成串刺激(TOF)为2时进行气管插管。使用50%氧气+50%空气和2%七氟醚维持麻醉。手术期间TOF为2时静脉注射0.15mg/kg罗库溴铵。手术结束时,静脉注射2mg/kg舒更葡糖钠。记录达到TOF 0.7、0.8和0.9的时间。
吸烟者的插管时间为132.8±46.4秒,非吸烟者为127.6±32.7秒。给予舒更葡糖钠后,吸烟者达到TOF 0.7的时间为153.3±